<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21445">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827695</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00053471</org_study_id>
    <nct_id>NCT02827695</nct_id>
  </id_info>
  <brief_title>Smart Phone Medication Adherence Saves Kidneys--SMASK</brief_title>
  <official_title>Smart Phone Medication Adherence Saves Kidneys--SMASK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will employ a 2-arm Randomized Controlled Trial (RCT) design with the subject
      as the unit of randomization and analysis. Kidney transplant recipients having uncontrolled
      hypertension will be enrolled into a screening phase to measure medication non-adherence.
      Each subject will use an electronic pill tray for 1 month without any reminder functions
      activated. Non-adherent subjects who remain uncontrolled will be randomly assigned to SMASK
      or Standard Care (SC). SC will continue to use the pill tray with reminders turned off and
      will receive attention control texts with healthy lifestyle information. SMASK will have the
      reminder functions of the electronic pill tray activated and will receive a Bluetooth blood
      pressure monitor and an app to collect the data and send to researchers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>six months</time_frame>
    <description>% with electronic monitor-derived adherence scores &gt;.90;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BP control</measure>
    <time_frame>Six months</time_frame>
    <description>% reaching and sustaining Kidney Disease Improving Global Outcomes (KDIGO) guidelines for BP control (resting and 24-hr BP&lt;130/80 mmHg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Provider adherence to KDIGO guidelines</measure>
    <time_frame>six months</time_frame>
    <description>measured by timing of medication changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Self-Determination Theory mediators</measure>
    <time_frame>six months</time_frame>
    <description>Survey responses demonstrate increased (e.g., perceived competence and autonomous regulation).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Medication Adherence</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>SMASK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive electronic pill tray with reminder functions activated and Bluetooth blood pressure monitor and phone app.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EnhancedSC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive daily attention control texts with healthy lifestyle information and continue to use the pill tray without reminder functions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SMASK</intervention_name>
    <description>Medication adherence and BP monitoring</description>
    <arm_group_label>SMASK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>EnhancedSC</intervention_name>
    <description>Standard care without med reminder functions with healthy lifestyle texts</description>
    <arm_group_label>EnhancedSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥21 years old;

          2. First time recipient of a functioning solitary kidney transplant;

          3. Prescribed ≥3 medications for immunosuppression and HTN;

          4. Transplant MD's assent that patient is able to participate;

          5. Ability to speak, hear and understand English;

          6. Able to take their own BP;

          7. Self-administers medications;

          8. SBP &gt;129 mmHg at clinic visit(s) in 4 weeks prior, and at initial study evaluation at
             enrollment;

          9. ***Only subjects with adherence score &lt;.85 after 1-month screening and SBP &gt;129 mmHg
             at baseline will be randomized.

        Exclusion Criteria:

          1. Failure to meet any inclusion criterion;

          2. Ongoing substance abuse (e.g., &gt;21 alcoholic drinks/week);

          3. Psychiatric illness requiring treatment beyond antidepressants;

          4. Will attempt to become pregnant within the year;

          5. Pregnant or nursing women, prisoners, and institutionalized persons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>john w mcgillicuddy, md</last_name>
      <email>mcgillij@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>frank a treiber, phd</last_name>
    </contact_backup>
    <investigator>
      <last_name>john w mcgillicuddy, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>July 7, 2016</lastchanged_date>
  <firstreceived_date>July 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
